Welcome To Alimera Sciences

We are a biopharmaceutical company that researches, develops and commercializes prescription ophthalmic pharmaceuticals. Our efforts are currently focused on diseases affecting the lining in the back of the eye, or retina, because these diseases are either not treated pharmacologically or are in need of improved treatments. As the world’s population continues to age, more and more people will be afflicted by these diseases. We created Alimera in June 2003, with the vision to bring innovative products to treat eye disease, specifically diseases that affect the retina, and to be guided by our experience of knowing the right things to do and our desire to “do the right thing” in our daily approach to the business. We invite you to learn more about us through our website.

Iluvien® (fluocinolone acetonide) intravitreal insert

Retinal disease treatment - IluvienIluvien, an innovative new product, is currently undergoing global clinical trials for the treatment of (DME). The FAME (Fluocinolone Acetonide in Diabetic Macular Edema) Study is tracking results of an innovative new intravitreal insert (smaller than a grain of rice as shown in the picture above) that is placed in the eye by a retinal specialist with a proprietary 25 gauge inserter. Iluvien then slowly releases a very low dose of the corticosteroid fluocinolone acetonide directly into the vitreous, the thick transparent substance that fills the center of the eye, for up to three years.
Learn more about Iluvien...
 
March 10, 2010

Alimera Announces Positive Results from the Two Phase 3 Fame™ Trials of Iluvien® in Patients with Diabetic Macular Edema

For the patients treated with the low dose of Iluvien, 26.8% to 30.6% demonstrated improvement in best corrected visual acuity (BCVA) of 15 letters from baseline, and for patients receiving the high dose of Iluvien, 26.0% to 31.2% demonstrated improvement of 15 or more letters in BCVA from baseline, both at 2 years. Company plans to file a New Drug Application (NDA) in the second quarter of 2010. Alimera Sciences receives notices of exercise for an additional $10 Million in extended Series C financing. Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported top-line results from the month 24 readout of the FAME Study.
 Read More...

ALIMERA REPORTS SAFETY AND EFFICACY RESULTS FROM THE 18-MONTH INTERIM READOUT OF THE HUMAN PK ILUVIEN® STUDY

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®.
 Read More...